Anika Therapeutics Inc (STU:AKP)
€ 18.6 +0.40 (+2.2%) Market Cap: 249.47 Mil Enterprise Value: 238.06 Mil PE Ratio: 0 PB Ratio: 2.10 GF Score: 66/100

Q1 2026 Anika Therapeutics Inc Earnings Call Transcript

Apr 29, 2026 / 12:30PM GMT
Release Date Price: €13.2 (+0.76%)

Key Points

Positve
  • Anika Therapeutics Inc (ANIK) reported a 13% year-over-year increase in total revenue for the first quarter of 2026, reaching $29.6 million.
  • The commercial channel revenue grew by 12%, driven by strong international execution and continued momentum in the Integrity product line.
  • The company's gross margin improved significantly to 64%, up from 56% in the prior year, due to higher manufacturing productivity and lean manufacturing efforts.
  • Anika Therapeutics Inc (ANIK) maintained a strong liquidity position with $41 million in cash and no debt, providing flexibility for future investments.
  • The company successfully completed a $15 million stock repurchase plan, reflecting a commitment to shareholder value.
Negative
  • The OEM channel is subject to variability related to customer order patterns, which may affect reported revenue in subsequent quarters.
  • Operating expenses increased to $24.5 million from $19 million in the prior-year period, partly due to $4.9 million in one-time severance-related costs.
  • R&D expenses rose by 11% to $6.6 million, reflecting continued investment in key regulatory and clinical programs.
  • The company faces challenges in expanding the adoption of its Integrity product, as augmentation is currently used in only about 8% of rotator cuff procedures in the U.S.
  • Anika Therapeutics Inc (ANIK) did not provide specific timelines for the completion of the Cingal bioequivalence study or the NDA filing, indicating potential delays in regulatory processes.
Operator

Good morning, ladies and gentlemen, and welcome to the Anika's first quarter earnings conference call.

I will now turn the call over to Mr Matt Hall. Executive Director, Corporate Development and Investor Relations. Please go ahead.

Matt Hall
Anika Therapeutics Inc - Director, Corporate Development and Investor Relations

Good morning, and thank you for joining us for Anika's first quarter 2026 conference call and webcast.

I'm Matt Hall, Anika's Executive Director of Corporate Development and Investor Relations. Our earnings press release was issued earlier this morning and is available on our Investor Relations website, located at www.anika.com, as are the supplementary PowerPoint slides that will be used for the discussion today.

With me on the call today are Steve Griffin, President and Chief Executive Officer, and Ian McLeod, Senior Vice President. Accounting Officer and Treasurer.

They will present our first quarter 2026 financial results and business

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot